Document:

PROMISSORY
NOTE

 

	$231,478.39	February
    27, 2019

 

RECITALS

 

WHEREAS
Immune Therapeutics, Inc (the “COMPANY” entered into an agreement with the Phoenix Group (“TPG”) on November
21, 2016.

 

WHEREAS
TPG has accrued monthly payments of $37,000 (thirty-seven thousand dollars) for the services of Mr. Rudy Williams and Dr. Vincent
Ahonkhai for the months of January 2018 through June of 2018 totaling $222,000 (two-hundred twenty-two thousand dollars).

 

WHEREAS
TPG has also incurred expenses totaling $9478.39 (nine-thousand four-hundred seventy-eight dollars and thirty-nine cents), with
a total owed amount $231,478.39 (Two-hundred thirty-one thousand four-hundred seventy-eight dollars and thirty-nine cents) “VALUE
OWED”.

 

WHEREAS,
TPG has requested that the Company provide TPG with a Promissory Note for the VALUE OWED bearing interest at a fixed rate as more
particularly described in this Agreement; and

 

WHEREAS,
the Company has agreed to provide TPG with a Promissory Note, subject to the terms and conditions set forth herein (as defined
below).

 

NOW,
THEREFORE, in consideration of the foregoing, the mutual covenants and agreements herein contained and other good and valuable
consideration the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows: for VALUE OWED, the undersigned,
Immune Therapeutics , Inc., a Florida corporation (referred to herein as the “Company” or the “Company”),
with offices at 2431 Aloma Ave, Suite 124 Winter Park, FL 32792 , hereby unconditionally promises to pay to the order of TPG,
its endorsees, successors and assigns, in lawful money of the United States, at such address as TPG may from time to time designate,
the principal sum of Two-hundred Thirty-one thousand four-hundred seventy-eight dollars and thirty-nine cents ($231,478.39). This
Promissory Note (the “Note”) shall mature and become due and payable in full on February 27, 2020 (the “Maturity
Date”).

 

1.
Terms of Repayment. Principal of and interest on this Note shall be paid by the Company as follows:

 

(a)
On the Maturity Date, Company shall pay all principal and interest. Interest shall accrue at a rate of Six Percent (6%) per annum
(the “Interest”).

 

(b)
The Company further agrees that, if any payment made by the Company or any other person is applied to this Note and is at any
time annulled, set aside, rescinded, invalidated, declared to be fraudulent or preferential or otherwise required to be refunded
or repaid, or the proceeds of any property hereafter pledged as security for this Note is required to be returned by TPG to the
Company, its estate, trustee, receiver or any other party, including, without limitation, under any bankruptcy law, state or federal
law, common law or equitable cause, then, to the extent of such payment or repayment, the Company’s liability hereunder
(and any lien, security interest or other collateral securing such liability) shall be and remain in full force and effect, as
fully as if such payment had never been made, or, if prior thereto any such lien, security interest or other collateral hereunder
securing the Company’s liability hereunder shall have been released or terminated by virtue of such cancellation or surrender,
this Note (and such lien, security interestor other collateral) shall be reinstated in full force and effect, and such prior cancellation
or surrender shall not diminish, release, discharge, impair or otherwise affect the obligations of the Company in respect to the
amount of such payment (or any lien, security interest or other collateral securing such obligation).

 

2.
Liability of the Company. The Company is unconditionally, and without regard to the liability of any other person,
liable for the payment and performance of this Note and such liability shall not be affected by an extension of time, renewal,
waiver, or modification of this Note or the release, substitution. Each person signing this Note consents to any and all extensions
of time, renewals, waivers, or modifications, as well as to release, substitution, or addition of guarantors or collateral security,
without affecting the Company’s liabilities hereunder. TPG is entitled to the benefits of any collateral agreement, guarantee,
security agreement, assignment, or any other documents which may be related to or are applicable to the debt evidenced by this
Note, all of which are collectively referred to as “Loan Documents” as they now exist, may exist in the future, have
existed, and as they may be amended, modified, renewed, or substituted.

 

    	 

     

    

 

3.
Representations and Warranties. The Company represents and warrants as follows: (i) the Company is a corporation
duly organized, validly existing and in good standing under the laws of the State of Florida; (ii) the execution, delivery and
performance by the Company of this Note are within the Company’s powers, have been duly authorized by all necessary action,
and do not contravene (A) the Company’s certificate of incorporation or (B) bylaws or (x) any law or (y) any agreement or
document binding on or affecting the Company, not otherwise disclosed to the TPG prior to execution of this Note, (iii) no authorization
or approval or other action by, and no notice to or filing with, any governmental authority, regulatory body or third person is
required for the due execution, delivery and performance by the Company of this Note; (iv) this Note constitutes the legal, valid
and binding obligation of the Company, enforceable against the Company in accordance with its terms except as enforcement hereof
may be limited by bankruptcy, insolvency or other similar laws affecting the enforcement of creditors’ rights generally
and subject to the applicability of general principles of equity; (v) the Company has all requisite power and authority to own
and operate its property and assets and to conduct its business as now conducted and proposed to be conducted and to consummate
the transactions contemplated hereby; (vi) the Company is duly qualified to conduct its business and is in good standing in each
jurisdiction in which the character of the properties owned or leased by it, or in which the transaction of its business makes
such qualification necessary; (vii) there is no pending or, to the Company’s knowledge, information or belief, threatened
action or proceeding affecting the Company before any governmental agency or arbitrator which challenges or relates to this Note
or which may otherwise have a material adverse effect on the Company; (viii) the Company is not in violation or default of any
provision of (A) its certificate of incorporation or by-laws, each as currently in effect, or (B) any instrument, judgment, order,
writ, decree or contract, statute, rule or regulation to which the Company is subject not otherwise disclosed to the TPG prior
to the execution of this Note, and (ix) this Note is validly issued, free of any taxes, liens, and encumbrances related to the
issuance hereof and is not subject to preemptive right or other similar right of members of the Company.

 

4.
Covenants. So long as any principal or interest is due hereunder and shall remain unpaid, the Company will, unless
the TPG shall otherwise consent in writing:

 

(a)
Maintain and preserve its existence, rights and privileges;

 

(b)
Not directly or indirectly sell, lease or otherwise dispose of (A) any of its property or assets other than in its ordinary course
of business or (B) substantially all of its properties and assets, in the aggregate, to any person(s) or company, whether in one
transaction or in a series of transactions over any period of time, or adopt any plan or arrangement for the dissolution or liquidation
of the Company;

 

(c)
Not use the proceeds from the issuance of this Note in any way for any purpose that entails a violation of, or is inconsistent
with, Regulation U of the Board of Governors of the Federal Reserve System of the United States of America.

 

(d)
Comply in all material respects with all applicable laws (whether federal, state or local and whether statutory. administrative
or judicial or other) and with every applicable lawful governmental order (whether administrative or judicial);

 

(e)
Not (i) make any advance or loan to any person, firm or corporation, except for reasonable travel or business expenses advanced
to the Company’s employees or independent contractors in the ordinary course of business, or (ii) acquire all or substantially
all of the assets of another entity;

 

(f)
Not prepay any indebtedness, except for trade payables incurred in the ordinary course of the Company’s business;

 

(g)
Maintain disclosure of Current Public Information as that term is defined in Rule 144(c) of the Securities Act, including proper
disclosure of this Note as required in its next quarter or annual filing; and

 

(h)
Not take any action which would impair the rights and privileges of this Note set forth herein or the rights and privileges of
the holder of this Note.

 

5.
Events of Default. Each and any of the following shall constitute a default and, after expiration of a grace period
which shall be Thirty (30) calendar days, shall constitute an “Event of Default” hereunder:

 

(a)
Non-payment of the Note pursuant to Section 1(a) will constitute an Event of Default.

 

(b)
any other failure of the Company to observe or perform any present or future agreement of any nature whatsoever with TPG, including,
without limitation, any covenant set forth in this Note;

 

(c)
if Company shall commence any case, proceeding or other action: (i) under any existing or future law of any jurisdiction, domestic
or foreign, relating to bankruptcy, insolvency, reorganization or relief of debtors, seeking to have an order for relief entered
with respect to it, or seeking to adjudicate it bankrupt or insolvent, or seeking reorganization, arrangement, adjustment, liquidation,
dissolution, composition or other relief with respect to it or its debts; or (ii) seeking appointment of a receiver, trustee,
custodian or other similar official for it or for all or any substantial part of its property, or the Company shall make a general
assignment for the benefit of its creditors; or (iii) there shall be commenced against the Company any case, proceeding or other
action of a nature referred to above or seeking issuance of a warrant of attachment, execution, distraint or similar process against
all or any substantial part of its property, which case, proceeding or other action results in the entry of any order for relief
or remains undismissed, undischarged or unbonded for a period of Sixty (60) days; or (iv) the Company shall take any action indicating
its consent to, approval of, or acquiescence in, or in furtherance of, any of the acts set forth; or (v) the Company shall generally
not, or shall be unable to, pay its debts as they become due or shall admit in writing its inability to pay its debts;

 

(d)
any representation or warranty made by the Company or any other person or entity under this Note or under any other Loan Documents
shall prove to have been incorrect in any material respect when made;

 

    	 

     

    

 

(e)
the sale of all or substantially all of the assets, or change in ownership or the dissolution, liquidation, consolidation, or
reorganization of Company without the TPG’s prior written notice;

 

(f)
if Company shall fail to maintain disclosure of Current Public Information as that term is defined in Rule 144(c) of the Securities
Act of 1933;

 

(g)
the Company’s shares of Common Stock are suspended from trading or delisted from trading on the Over the Counter Market
on which it is currently listed;

 

(h)
if the Company fails to disclose the existence of this Note in its next quarter or annual filing;

 

(i)
in the event that the Company proposes to replace or replaces its transfer agent and the Company fails to provide, prior to the
effective date of such replacement, a fully executed Transfer Agent Instructions in a form as initially delivered pursuant to
the terms of this Note (including but not limited to the provision to reserve shares of Common Stock) signed by the successor
transfer agent to Company and the Company.

 

6.
TPG’s Rights Upon Default. Upon the occurrence of any Event of Default, the TPG may, at its sole and exclusive
option, do any or all of the following, either concurrently or separately: (a) accelerate the maturity of this Note and demand
immediate payment in full, whereupon the outstanding principal amount of the Note and all obligations of Company to TPG, together
with accrued interest thereon and accrued charges and costs, shall become immediately due and payable without presentment, demand,
protest or further notice of any kind, all of which are hereby expressly waived; and (b) exercise all legally available rights
and privileges.

 

7.
Usury. In no event shall the amount of interest paid or agreed to be paid hereunder exceed the highest lawful rate
permissible under applicable law. Any excess amount of deemed interest shall be null and void and shall not interfere with or
affect the Company’s obligation to repay the principal of and interest on the Note. This confirms that the Company and,
by its acceptance of this Note, the TPG intend to contract in strict compliance with applicable usury laws from time to time in
effect. Accordingly, the Company and the TPG stipulate and agree that none of the terms and provisions contained herein shall
ever be construed to create a contract to pay, for the use or forbearance of money, interest in excess of the maximum amount of
interest permitted to be charged by applicable law from time to time in effect.

 

8.
Prepayment. The Company may prepay the Note including accrued but unpaid Interest at any time.

 

9.
Costs of Enforcement. Company hereby covenants and agrees to indemnify, defend and hold TPG harmless from and against
all costs and expenses, including reasonable attorneys’ fees and their costs, together with interest thereon at the Prime
Rate, incurred by TPG in enforcing its rights under this Note; or if TPG is made a party as a defendant in any action or proceeding
arising out of or in connection with its status as a TPG, or if TPG is requested to respond to any subpoena or other legal process
issued in connection with this Note; or reasonable disbursements arising out of any costs and expenses, including reasonable attorneys’
fees and their costs incurred in any bankruptcy case; or for any legal or appraisal reviews, advice or counsel performed for TPG
following a request by Company for waiver, modification or amendment of this Note or any of the other Loan Documents.

 

10.
Governing Law. This Note shall be binding upon and inure to the benefit of the Company and the TPG and their respective
successors and assigns; provided that the Company may not assign this Note, in whole or in part, by operation of law or otherwise,
without the prior written consent of the TPG. The TPG may assign or otherwise participate out all or part of, or any interest
in, its rights and benefits hereunder and to the extent of such assignment or participation such assignee shall have the same
rights and benefits against the Company as it would have had if it were the TPG. This Note, and any claims arising out of relating
to this Note, whether in contract or tort, statutory or common law, shall be governed exclusively by, and construed in accordance
with the laws of the State of Florida, without regard to principles of conflicts of laws.

 

11.
Jurisdiction. THE COMPANY CONSENTS THAT ANY LEGAL ACTION OR PROCEEDING AGAINST IT UNDER, ARISING OUT OF OR IN ANY
MANNER RELATING TO THIS NOTE, OR ANY OTHER INSTRUMENT OR DOCUMENT EXECUTED AND DELIVERED IN CONNECTION HEREWITH SHALL BE BROUGHT
EXCLUSIVELY IN ANY COURT OF THE STATE OF FLORIDA OR IN THE UNITED STATES DISTRICT COURT FOR THE MIDDLE DISTRICT OF FLORIDA. THE
COMPANY, BY THE EXECUTION AND DELIVERY OF THIS NOTE, EXPRESSLY AND IRREVOCABLY CONSENTS AND SUBMITS TO THE PERSONAL JURISDICTION
OF ANY OF SUCH COURTS IN ANY SUCH ACTION OR PROCEEDINGS. THE COMPANY AGREES THAT PERSONAL JURISDICTION OVER IT MAY BE OBTAINED
BY THE DELIVERY OF A SUMMONS BY PERSONAL DELIVERY OR OVERNIGHT COURIER AT THE ADDRESS PROVIDED IN THIS NOTE. ASSUMING DELIVERY
OF THE SUMMONS IN ACCORDANCE WITH THIS PROVISION, THE COMPANY HEREBY EXPRESSLY AND IRREVOCABLY WAIVES ANY ALLEGED LACK OF PERSONAL
JURISDICTION, IMPROPER VENUE OR FORUM NON-CONVENIENS OR ANY SIMILAR BASIS.

 

12.
Miscellaneous. (a) Company hereby waives protest, notice of protest, presentment, dishonor, and demand. (b) Time
is of the essence for each of Company’s covenants under this Note. (c) The rights and privileges of TPG under this Note
shall inure to the benefit of its successors and assigns. All obligations of Company in connection with this Note shall bind Company’s
successors and assigns, and TPG’s rights shares of the Company shall succeed to any successor securities to Company’s
common stock. (d) If any provision of this Note shall for any reason be held to be invalid or unenforceable, such invalidity or
unenforceability shall not affect any other provision hereof, but this Note shall be construed as if such invalid or unenforceable
provision had never been contained herein. (e) The waiver of any Event of Default or the failure of TPG to exercise any right
or remedy to which it may be entitled shall not be deemed a waiver of any subsequent Event of Default or TPG’s right to
exercise that or any other right or remedy to which TPG is entitled. No delay or omission by TPG in exercising, or failure by
TPG to exercise on anyone or more occasions, shall be construed as a waiver or novation of this Note or prevent the subsequent
exercise of any or all such rights. (f) This Note may not be waived, changed, modified, or discharged orally, but only in writing.

 

    	 

     

    

 

13.
Notice, Etc. Any notice required by the provisions of this Note will be in writing and will be deemed effectively
given: (a) upon personal delivery to the party to be notified; (b) when sent by confirmed telex or facsimile if sent during normal
business hours of the recipient; if not, then on the next business day; (c) Five (5) days after having been sent by registered
or certified mail, return receipt requested, postage prepaid; or (d) One (1) day after deposit with a nationally recognized overnight
courier, specifying next day delivery, with written verification of receipt, and delivered as follows:

 

If
to Company

 

Immune
Therapeutics Inc

2431
Aloma Ave, Suite 124

Winter
Park, FL 32792

 

If
to the TPG:

The
Phoenix Group

 

or,
as to each party, at such other address as shall be designated by such party in a written notice to the other parties.

 

[SIGNATURE
PAGE TO FOLLOW]

 

The
remainder of this page is intentionally left blank.

 

    	 

     

    

 

IN
WITNESS WHEREOF, the undersigned has executed this Promissory Note as of the date first set forth above.

 

THE
COMPANY

 

Immune
Therapeutics, Inc.

 

	By:
    	 	 
	Name:
    	Noreen
    Griffin	 
	Title:
    	CEO	 

 

TPG

 

The
Phoenix Group

 

	By:	 	 
	Name:
    	 	 
	Title:SECOND
AMENDMENT TO LICENSE AGREEMENT

 

This
Second Amendment to License Agreement (“Second Amendment”) is effective December 31, 2018 (“Effective
Date”), by and between: Cytocom Inc., a for profit corporation duly organized and existing under the laws of the Commonwealth
of Delaware, having an office at 37 North Orange Ave Suite 607 Orlando Florida 32801 (“CYTO”), and Immune Therapeutics
Inc., a Florida Corporation formerly doing business as TNI BioTech, Inc., having an office at 2431 Aloma Ave #124 Winter Park,
FL 32792 (“IMUN and or Company or Licensee”). CYTO and Licensee may each be referred to individually as “Party”
and collectively as “Parties”.

 

WITNESSETH

 

WHEREAS,
the Parties entered into that certain Amended License Agreement, effective May 1, 2018 (the “License Agreement”);
and

 

WHERAS,
as a consequence of the License Agreement, the Company deconsolidated CYTO as of May 1, 2018 in its financial reporting, and now
accounts for its retained interest in CYTO under the equity method of accounting;

 

WHERAS,
as a consequence of the deconsolidation of CYTO in the Company’s financial reporting, the Parties wish to clarify and confirm
which obligations of the Parties incurred by either Party before the Effective Date will become the sole obligations of CYTO on
and after the Effective Date;

 

WHEREAS,
the Parties desire to further amend the License Agreement to provide for the assumption of additional obligations of CYTO by IMUN
as consideration for the agreement that China will be included as a Territory under the License Agreement;

 

NOW
THEREFORE, in consideration of the foregoing and the mutual promises and covenants set forth herein and for good and valuable
consideration, the adequacy and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows:

 

1.       Definitions.
For purposes of this Second Amendment, all capitalized terms shall have the meaning ascribed by the License Agreement unless expressly
amended herein.

 

1.1       “Territory”
means, all countries listed in the License Agreement signed May 1, 2018, together with the Republic of China.

 

1.2       “Accounts
Payable “means those accounts payable obligations and accrued liabilities as specified in Schedule 1 “Cytocom
Inc. Accounts Payable and Accrued Obligations” attached hereto.

 

1.6       “Notes
Payable” means those obligations owed under certain promissory notes as specified in Schedule 2 “Cytocom
Inc. Notes Payable” hereto.

 

2.       Confirmation
of Ownership of Cytocom Inc, by Company. The Parties confirm and agree that in accordance with the Stock Purchase Agreement
signed by the Parties on June 4, 2018, as of the Effective Date IMUN owns common stock of CYTO representing 15.57% of the outstanding
common shares of CYTO as of the Effective Date, and that, in the event that CYTO issues additional shares after the Effective
Date and up to and including the completion of a Series A round in an amount greater than $3 million, or IPO, or Sale of CYTO,
CYTO will cause additional shares to be issued to IMUN in such number that IMUN’s percentage of outstanding common stock
will not fall below 15.57%.

 

    	 	Page 1 of 5	 

    	 	 	 

    

 

3.       Assumption
of Accounts Payable. The Parties agree that IMUN shall assume the obligation to repay all accounts payable obligations and
accrued liabilities owed by CYTO as of the Effective Date, except those accounts payable obligations and accrued liabilities as
specified in Schedule 1 “Cytocom Inc. Accounts Payable and Accrued Obligations” attached hereto, which shall continue
to be obligations of CYTO on and after the date of this Second Amendment.

 

4.       Assumption
of Notes Payable. The Parties agree that IMUN shall assume the obligation to repay all notes payable, together with any interest
or fees payable thereon, owed by CYTO as of the Effective Date, except those notes payable obligations, together with any interest
or fees payable thereon, as specified in Schedule 2 “Cytocom Inc. Notes Payable” attached hereto, which shall continue
to be obligations of CYTO on and after the date of this Second Amendment.

 

5.
       Buyout. In the event of a Change of Control of CYTO, and at the option of CYTO,
the Company shall have the right to purchase outright the Company’s licensing rights to Emerging Markets for humans under
the License Agreement at a price equal to the value of those licensing rights as determined by an independent valuator acceptable
to the Company and CYTO, which determination shall be final and binding. The cost of said valuation will be paid for by CYTO.

 

6.       Interpretation.
Except to the extent specifically amended by this Second Amendment, all terms and conditions set forth in the License Agreement
shall remain unchanged and in full force and effect.

 

7.       Entire
Agreement. This Second Amendment, in conjunction with the License Agreement, constitutes the entire agreement between the
Parties regarding the subject matter hereof and supersedes any prior understandings, agreements or representations between the
Parties, written or oral, relating to the subject matter hereof.

 

8.       Counterparts.
This Second Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original as against
a Party whose signature appears thereon, and each of which shall together constitute one and the same instrument. Any counterpart
signature page delivered by electronic means or by facsimile transmission shall be deemed to have the same force and effect as
an originally executed signature page.

 

[SIGNATURES
APPEAR ON FOLLOWING PAGE]

 

    	 	Page 2 of 5	 

    	 	 	 

    

 

IN
WITNESS WHEREOF, the Parties, intending to be legally bound hereby, have each caused a duly authorized representative to execute
this Second Amendment on the day and year set forth below.

 

	LICENSEE:	 
	Immune
    Therapeutics, Inc.	 
	 	 	 
	By:	 	 
	Name	Noreen
    Griffin	 
	Title:	Chief
    Executive Officer	 
	Date:	April
    8, 2019	 
	 	 	 
	LICENSOR:	 
	Cytocom,
    Inc.	 
	 	 	 
	By:	 	 
	Name:	Noreen
    Griffin	 
	Title:	President	 
	Date:	April
    8, 2019	 

 

    	 	Page 3 of 5	 

    	 	 	 

    

 

Schedule
1

 

Cytocom
Inc. Accounts Payable and Accrued Obligations 

 

	Vendors and Accounts Payable	 	Amount ($)	 
	LDN Research Group LLC	 	$	74,670.00	 
	Elisa DeLaet Jagerson	 	 	37,500.00	 
	Dr. Jill Smith	 	 	24,669.98	 
	Aronstam Management Services Inc	 	 	24,000.00	 
	Birch Stewart Kolash Birch LLP	 	 	20,569.76	 
	Molski Management Services Inc	 	 	16,666.67	 
	The Pennsylvania State University	 	 	8,747.41	 
	Husch Blackwell LLP	 	 	4,586.70	 
	ClearTrust, LLC	 	 	750.00	 
	Corporate Creations	 	 	561.85	 
	Dr. Nicholas J. Sisti Esq.	 	 	(500.00	)
	TOTAL	 	$	212,222.37	 

 

	Creditors and Accrued Liabilities	 	Amount ($)	 
	Noreen Griffin	 	$	520,000.00	 
	Kelly Wilson	 	 	32,000.00	 
	Robert Wilson	 	 	32,000.00	 
	TOTAL	 	$	584,000.00	 

 

    	 	Page 4 of 5	 

    	 	 	 

    

 

Schedule
1

 

Cytocom
Inc. Notes Payable

 

	Borrower at Date of Note Signing	 	Effective 
Date of Note	 	Lender	 	Principal Amount of Note ($)	 	 	Maturity 
Date	 	Accrued Interest and Fees at 12/31/20118 ($)	 	 	Total Owing at

                                                                                 12/31/2018
 ($)
	 
	Cytocom	 	6/16/2015	 	MJW Properties	 	$	25,000.00	 	 	9/30/2015	 	$	3,775.00	 	 	$	28,775.00	 
	Cytocom	 	9/30/2015	 	Richard Gostanian	 	 	400,000.00	 	 	9/30/2016	 	 	104,153.42	 	 	 	504,153.42	 
	Cytocom	 	1/8/2016	 	RJ Dailey	 	 	80,000.00	 	 	1/8/2017	 	 	23,846.58	 	 	 	103,846.58	 
	Cytocom	 	2/8/2016	 	Paul Akin	 	 	50,000.00	 	 	2/8/2017	 	 	14,479.45	 	 	 	64,479.45	 
	Immune	 	3/9/2016	 	Paul Akin	 	 	20,000.00	 	 	3/8/2017	 	 	5,705.56	 	 	 	25,705.56	 
	Immune	 	4/11/2016	 	P Akin-QS	 	 	21,000.00	 	 	4/11/2017	 	 	5,798.33	 	 	 	26,798.33	 
	Immune	 	9/30/2016	 	Paul Akin	 	 	20,000.00	 	 	9/30/2017	 	 	1,959.00	 	 	 	21,959.00	 
	Immune	 	9/30/2016	 	Paul Akin	 	 	25,000.00	 	 	9/30/2017	 	 	2,448.75	 	 	 	27,448.75	 
	Immune	 	9/30/2016	 	Paul Akin	 	 	33,000.00	 	 	9/30/2017	 	 	3,232.35	 	 	 	36,232.35	 
	Immune	 	9/30/2016	 	Paul Akin	 	 	6,000.00	 	 	9/30/2017	 	 	587.70	 	 	 	6,587.70	 
	Immune	 	10/7/2016	 	Paul Akin	 	 	10,000.00	 	 	10/7/2017	 	 	975.42	 	 	 	10,975.42	 
	Immune	 	11/1/2016	 	Richard Gostanian	 	 	275,000.00	 	 	11/1/2017	 	 	26,422.92	 	 	 	301,422.92	 
	Immune	 	11/1/2016	 	RJ Dailey	 	 	275,000.00	 	 	11/1/2017	 	 	26,422.92	 	 	 	301,422.92	 
	Immune	 	12/31/2016	 	Richard Gostanian	 	 	30,000.00	 	 	2/18/1982	 	 	2,777.50	 	 	 	32,777.50	 
	Immune	 	3/31/2017	 	RJ Dailey	 	 	165,000.00	 	 	3/31/2018	 	 	14,410.00	 	 	 	179,410.00	 
	Immune	 	3/31/2017	 	Paul Akin	 	 	5,000.00	 	 	3/31/2018	 	 	436.67	 	 	 	5,436.67	 
	Immune	 	4/3/2017	 	RJ Dailey	 	 	150,000.00	 	 	4/3/2018	 	 	13,073.75	 	 	 	163,073.75	 
	Immune	 	9/30/2017	 	Paul Akin	 	 	25,000.00	 	 	9/30/2018	 	 	1,916.46	 	 	 	26,916.46	 
	Cytocom	 	3/31/2018	 	Jared Kroeger	 	 	50,000.00	 	 	3/31/2019	 	 	1,909.72	 	 	 	51,909.72	 
	Cytocom	 	3/31/2018	 	Richard Gostanian	 	 	101,000.00	 	 	3/31/2019	 	 	3,857.64	 	 	 	104,857.64	 
	Cytocom	 	3/31/2018	 	RJ Dailey	 	 	70,000.00	 	 	3/31/2019	 	 	6,307.29	 	 	 	76,307.29	 
	Cytocom	 	3/31/2018	 	Susan St Ledger	 	 	75,000.00	 	 	3/31/2019	 	 	2,864.58	 	 	 	77,864.58	 
	Cytocom	 	5/14/2018	 	Susan St Ledger	 	 	50,000.00	 	 	5/14/2019	 	 	1,604.17	 	 	 	51,604.17	 
	Cytocom	 	6/30/2018	 	Paul Akin	 	 	10,000.00	 	 	6/30/2019	 	 	255.56	 	 	 	10,255.56	 
	Cytocom	 	6/30/2018	 	Richard Gostanian	 	 	37,500.00	 	 	6/30/2019	 	 	958.33	 	 	 	38,458.33	 
	Cytocom	 	6/30/2018	 	RJ Dailey	 	 	50,000.00	 	 	6/30/2019	 	 	1,277.78	 	 	 	51,277.78	 
	Cytocom	 	7/1/2018	 	Alan Cunningham (replace)	 	 	83,000.00	 	 	7/1/2019	 	 	2,080.68	 	 	 	85,080.68	 
	Cytocom	 	7/13/2018	 	Alan Cunningham	 	 	10,000.00	 	 	7/13/2019	 	 	237.50	 	 	 	10,237.50	 
	Cytocom	 	8/23/2018	 	Richard Kelley	 	 	10,000.00	 	 	12/23/2018	 	 	575.83	 	 	 	10,575.83	 
	Cytocom	 	9/30/2018	 	Richard Gostanian	 	 	62,000.00	 	 	9/30/2019	 	 	792.22	 	 	 	62,792.22	 
	Cytocom	 	9/30/2018	 	RJ Dailey	 	 	30,000.00	 	 	9/30/2019	 	 	383.33	 	 	 	30,383.33	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	TOTAL	 	 	 	 	 	$	2,253,500.00	 	 	 	 	$	275,526.41	 	 	$	2,529,026.41	 

 

    	 	Page 5 of 5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00296-of-00352.parquet"}]]